Fig. 3: Interactions between OV and inflammatory monocytes promote better infection of the initial OV dose. | Communications Biology

Fig. 3: Interactions between OV and inflammatory monocytes promote better infection of the initial OV dose.

From: Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes

Fig. 3

a Luminescence intensity for CT26LacZ tumors during a 2-dose OVT schedule (106 PFU) with or without CLL treatment 24 h after the first virus administration. VSV-FLUC was administered as a second dose 48 h after initial treatment with VSV-NR. Results are shown as mean with individual values (n = 5); two-way ANOVA. b Bioluminescence images for the groups shown in (a) 48 h after administration of the second dose of VSV. c, d Luminescence intensities for CT26LacZ tumors during a 2 dose OVT schedule (106 PFU VSV-FLUC, 48 h between doses) with or without monocyte depletion by CLL (c) or anti-CCR2 antibody (d) administered between viral doses. Results are shown as mean with individual values (n = 5 (c); n = 7 (d)); two-way ANOVA. e Tumor measurements for CT26LacZ-bearing mice treated with one or two doses of VSV-FLUC (106 PFU, 48 h between i.v. injections) ±anti-CCR2. Results are shown as mean ± SEM (n = 5); two-way ANOVA followed by Sidak’s multiple comparisons test. f Kaplan–Meier survival plots for animals treated with one or two doses of VSV-FLUC ± anti-CCR2; log-rank test.

Back to article page